EP Patent

EP4282415A1 — A stable tablet composition of axitinib

Assigned to Genepharm SA · Expires 2023-11-29 · 2y expired

What this patent protects

A stable tablet composition of Axitinib comprising crystalline form IV Axitinib in the range of 1 to 10%; reducing sugar(s) in the range of 0.5 to 15%; at least one pharmaceutical excipient(s) selected from disintegrant, diluent, binder, lubricant, antioxidant and glidant; and wh…

USPTO Abstract

A stable tablet composition of Axitinib comprising crystalline form IV Axitinib in the range of 1 to 10%; reducing sugar(s) in the range of 0.5 to 15%; at least one pharmaceutical excipient(s) selected from disintegrant, diluent, binder, lubricant, antioxidant and glidant; and wherein the % is weight by weight of the tablet composition and wherein the composition is bioequivalent to axitinib product (Inlyta<sup>®</sup>).

Drugs covered by this patent

Patent Metadata

Patent number
EP4282415A1
Jurisdiction
EP
Classification
—
Expires
2023-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Genepharm SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.